December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.2468 -0.0012 (-0.48%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,635,821
Open 0.2563
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2480
Today's Range 0.2268 - 0.2563
52wk Range 0.2050 - 0.3970
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire

Performance

YTD
-8.6%
-8.6%
1 Month
-26.7%
-26.7%
3 Month
-14.6%
-14.6%
6 Month
-11.9%
-11.9%
1 Year
-19.4%
-19.4%

More News

Read More
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
From BioMedWire
Via GlobeNewswire
News headline image
CytoDyn to Present at the LD Micro Invitational XVI
From CytoDyn Inc.
Via GlobeNewswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
Via Investor Brand Network
Topics Intellectual Property
News headline image
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
CytoDyn to Host Investor Webcast
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present at the AACR Annual Meeting 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
From CytoDyn Inc.
Via GlobeNewswire
News headline image
December 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Resolution of Class Action Lawsuit
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire

Frequently Asked Questions

Is Cytodyn Inc publicly traded?
Yes, Cytodyn Inc is publicly traded.
What exchange does Cytodyn Inc trade on?
Cytodyn Inc trades on the OTC Traded
What is the ticker symbol for Cytodyn Inc?
The ticker symbol for Cytodyn Inc is CYDY on the OTC Traded
What is the current price of Cytodyn Inc?
The current price of Cytodyn Inc is 0.2468
When was Cytodyn Inc last traded?
The last trade of Cytodyn Inc was at 06/26/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.